{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-013498","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.518590+00:00","generated_at":"2026-06-06T19:03:07.752929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elevance Health Q4 adj EPS $5.62 (+15.2% YoY); FY 2024 outlook above $37.10","bullets":["Q4 GAAP diluted EPS $3.63 (+1.1% YoY); adjusted diluted EPS $5.62 (+15.2% YoY).","Q4 operating revenue $42.5B, up 7% YoY; full-year revenue $170.2B, up 9.3% YoY.","FY 2024 guidance: GAAP EPS >$34.29, adjusted EPS >$37.10; quarterly dividend raised 10.1% to $1.63.","Medical membership 47.0M, down 570k YoY from Medicaid redeterminations; Health Benefits operating gain +14% for the year.","Operating cash flow $8.1B in 2023; repurchased 5.8M shares for $2.7B during the year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-013498","json":"https://secwatch.observer/filing/0001193125-24-013498.json","markdown":"https://secwatch.observer/filing/0001193125-24-013498.md","text":"https://secwatch.observer/filing/0001193125-24-013498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/d736006d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:03:07.752929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"037a73f08f956cb41b400cb0827f069e18957c71","claim":"Elevance Health, Inc. reported FY 2023 results: revenue $170 billion, EPS $25.22.","evidence_excerpt":"FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS 2 of $5.62, up 15.2%; FY 2023 GAAP diluted EPS of $25.22, up 3.9% from FY 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2023"},{"label":"Revenue","value":"$170 billion"},{"label":"EPS","value":"$25.22"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3f00eb5a45a841aaa8a472296f73ce92a7337506","claim":"Elevance Health, Inc. reported Q4 2023 results: revenue $42.5 billion, EPS $3.63.","evidence_excerpt":"4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2023"},{"label":"Revenue","value":"$42.5 billion"},{"label":"EPS","value":"$3.63"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e5d269322b42a0bd27cce044fb6740350a49420b","claim":"Elevance Health, Inc. reported FY 2024 results: EPS greater than $34.29. Guidance initiated.","evidence_excerpt":"Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS 2 of greater than $34.29 and $37.10 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2024"},{"label":"EPS","value":"greater than $34.29"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}